Patents by Inventor Guillermo Mor

Guillermo Mor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOPTOSIS-BASED EVALUATION OF CHEMOSENSITIVITY IN CANCER PATIENTS
    Publication number: 20100173341
    Abstract: Induction of apoptosis in target cells is a key mechanism by which chemotherapy induces cell killing. An in vitro system has been established for determining carboplatin and paclitaxel (Taxol) chemosensitivity of epithelial ovarian cancer cells, where measurements of caspase-3 activation are surrogate markers for activation of chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemosensitivity in vitro apoptotic response were compared to the clinical response of the patients from whom the tumor cells were isolated. Caspase-3 activation in response to in vitro chemotherapy to both drugs was shown to have an 83% positive predictive value and a 71% negative predictive value. Markers of apoptosis such as caspase-3 activation can be quantitated and utilized to predict the clinical response to chemotherapy.
    Type: Application
    Filed: January 19, 2010
    Publication date: July 8, 2010
    Applicant: Yale University
    Inventor: Guillermo Mor
  • Apoptosis-based evaluation of chemosensitivity in cancer patients
    Patent number: 7674579
    Abstract: Induction of apoptosis in target cells is a key mechanism by which chemotherapy induces cell killing. An in vitro system has been established for determining carboplatin and paclitaxel (Taxol) chemosensitivity of epithelial ovarian cancer cells, where measurements of caspase-3 activation are surrogate markers for activation of chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemotherapy-induced programmed cell death. To validate the assay as a predictor of clinical chemosensitivity in vitro apoptotic response were compared to the clinical response of the patients from whom the tumor cells were isolated. Caspase-3 activation in response to in vitro chemotherapy to both drugs was shown to have an 83% positive predictive value and a 71% negative predictive value. Markers of apoptosis such as caspase-3 activation can be quantitated and utilized to predict the clinical response to chemotherapy.
    Type: Grant
    Filed: November 26, 2004
    Date of Patent: March 9, 2010
    Assignee: Yale University
    Inventor: Guillermo Mor
  • In vitro test to detect risk of preeclampsia
    Publication number: 20050074746
    Abstract: The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
    Type: Application
    Filed: February 13, 2004
    Publication date: April 7, 2005
    Inventors: Guillermo Mor, Donna Neale, Roberto Romero